Clearmind Medicine Treats 20 Participants in CMND-100 AUD Trial, Advances to Higher Dose Cohort
Summary
Clearmind Medicine announced a clinical milestone, having treated 20 participants in its Phase I/IIa trial for CMND-100 for Alcohol Use Disorder, with dosing initiated in the higher-dose fourth cohort.
Key Events
-
Clinical Trial Milestone Reached
A total of 20 participants have now been treated across all cohorts in the FDA-approved Phase I/IIa clinical trial for CMND-100, targeting Alcohol Use Disorder (AUD).
-
Advancement to Higher Dose Cohort
Two additional participants have been successfully dosed in the fourth cohort, which features a higher dose of CMND-100 (160 mg), following Data and Safety Monitoring Board (DSMB) approval.
-
Positive Safety Data Continues
The trial continues to demonstrate a favorable safety and tolerability profile, with no serious adverse events reported across the first three cohorts (18 participants).
Analysis
This filing details continued progress in Clearmind Medicine's Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder. Reaching 20 treated participants and advancing to a higher dose cohort after positive safety data from previous cohorts is a significant de-risking step for a clinical-stage biotech company. Consistent positive safety and tolerability data are crucial for moving forward in drug development, especially for a company of this size, as it validates the drug's profile and extends its development runway.
At the time of this filing, CMND was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.52 to $52.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.